PharmaShots | Incisive News in 3 Shots

Subscribe Now

Sangamo Therapeutics

Sangamo Therapeutics Receives the US FDA’s IND Approval for ST-503 to Treat Idiopathic Small Fiber Neuropathy

Sangamo Therapeutics Receives the US FDA’s IND Approval for ST-503 to Treat Idiopathic Small Fiber Neuropathy

November 20, 2024

Sangamo Therapeutics Signs a Research Evaluation and Option Agreement with Prevail, a Wholly Owned Subsidiary of Lilly for Novel Engineered Capsids

Sangamo Therapeutics Signs a Research Evaluation and Option Agreement with Prevail, a Wholly Owned Subsidiary of Lilly for Novel E...

July 18, 2023

Bettina Cockroft, SVP & CMO at Sangamo Therapeutics Shares Insights from the Positive P-I/II Data for Fabry Disease Treatment

Bettina Cockroft, SVP & CMO at Sangamo Therapeutics Shares Insights from the Positive P-I/II Data for Fabry Disease Treatment

April 25, 2023

Sangamo Therapeutics Reports Results of ST-920 in P-I/II (STAAR) Study for the Treatment of Fabry Disease

Sangamo Therapeutics Reports Results of ST-920 in P-I/II (STAAR) Study for the Treatment of Fabry Disease

August 30, 2022

Contact Us

First Floor, B-66, Sector 63 Noida, Uttar Pradesh, INDIA - 201301
+91-120 428 0707
connect@pharmashots.com
Newsletter

Our Information

Follow Us